FDA approves daraxonrasib for patients with metastatic pancreatic cancer
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to…
New study identifies key pathway for delivering antisense cancer drugs
Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins…
New drug delivers promising survival gains in pancreatic cancer
About 90% of people with pancreatic cancer have pancreatic ductal adenocarcinoma (PDAC), which is driven by an activating mutation in…
Engineered probiotic bacteria boost immune attack against pancreatic cancer
Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major…
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Red meat intake emerges as a potential pancreatic cancer risk factor
A review of nearly 2 million participants links higher red meat intake to pancreatic cancer risk, while the…
Blood-based gene tests show promise for pancreatic cancer screening
Researchers at Kanazawa University report the blood-based gene expression tests may enable early pancreatic cancer screening and improve…
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Microbiome science merges with oncology for better cancer treatments
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to…
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What’s Next
In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D…
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Targeted therapy doubles progression-free survival in rare bile duct cancer
Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid…